#### Edgar Filing: BRUM LYNNE H - Form 4

BRUM LYN Form 4 February 22,										
								OMB AF	PROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSI Washington, D.C. 20549							OMMISSION	OMB Number:	3235-0287	
Check this	<u> </u>					Expires:	January 31,			
subject to Section 16. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Estimate burden								Estimated a burden hour response		
(Print or Type R	Responses)									
1. Name and Ad BRUM LYN	lssuer Name and bol RTEX PHAR C / MA [VRT2	MACEU		-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last)	ate of Earliest Tr nth/Day/Year)	-			Director 10% Owner X Officer (give title Other (specify					
C/O VERTE PHARMACI INCORPOR STREET			21/2006				below) VP, Strate	below) gic Communica	ations	
	Amendment, Da d(Month/Day/Year)	-	1		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
CAMBRIDO	GE, MA 02139						Form filed by M Person	Iore than One Re	porting	
(City)	(State) (	(Zip)	Table I - Non-D	erivative	Secur	rities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Transaction Date 2A. Deemed Aonth/Day/Year) Execution Date, if any (Month/Day/Year)				cquired d of (D) 5) Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		ndirect (I) Ownership	
Common Stock	02/21/2006		Code V M	1,000	A	\$ 15.56	49,587	D		
Common Stock	02/21/2006		S <u>(1)</u>	1,000	D	\$ 37.13	48,587	D		
Common Stock							6,793	Ι	401(k)	
Common Stock							10	Ι	Owned by husband	

#### Edgar Filing: BRUM LYNNE H - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	\$ 15.56	02/21/2006		А	1,000	03/12/1997(2)	12/11/2006	Common Stock	1,000

## **Reporting Owners**

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
BRUM LYNNE H C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE, MA 02139			VP, Strategic Communications		
Signatures					

# S

C

Kenneth S. Boger, Attorney-In-Fact

02/22/2006

\*\*Signature of Reporting Person

Date

### **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Ms. Brum's company approved trading plan established under Rule 10b5-1.
- (2) Right to buy under 1996 Stock and Option Plan, vesting quarterly over 5 years from 12/12/96.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.